The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance (Q39227285)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2013

Language	Label	Description	Also known as
English	The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance	scientific article published on March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

author name string

Matthew J Sale

1

1 reference

Europe PubMed Central

10 September 2017

Simon J Cook

2

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

1 March 2013

1 reference

Europe PubMed Central

10 September 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Biochemical Journal

1 reference

Europe PubMed Central

10 September 2017

450

1 reference

Europe PubMed Central

10 September 2017

2

1 reference

Europe PubMed Central

10 September 2017

285-294

1 reference

Europe PubMed Central

10 September 2017

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

BRAF mutations in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

The role of Bcl-2 family members in tumorigenesis

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Tumour cell survival signalling by the ERK1/2 pathway

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

ARC synergizes with ABT-737 to induce apoptosis in human cancer cells

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1042%2FBJ20121212

21 January 2018

Identifiers

10.1042/BJ20121212

1 reference

Europe PubMed Central

10 September 2017

release_37iib3ik3rda5jbnbc47vk5nbm

0 references

1 reference

Europe PubMed Central

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39227285&oldid=2088818389"